Central pontine myelinolysis primary prevention: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
To prevent central pontine myelinolysis in patients with [[hyponatremia]], the [[hyponatremia]] should be corrected at a rate not exceeding 10 mmol/L/24 h or 0.5 mEq/L/h; or 18 mEq/L/48hrs to minimize the risk of this condition developing from the overly rapid reversal of [[hyponatremia]], thus avoiding [[demyelination]]. | |||
==Primary Prevention== | ==Primary Prevention== | ||
To prevent central pontine myelinolysis in patients with [[hyponatremia]], the [[hyponatremia]] should be corrected at a rate not exceeding 10 mmol/L/24 h or 0.5 mEq/L/h; or 18 mEq/L/48hrs to minimize the risk of this condition developing from the overly rapid reversal of [[hyponatremia]], thus avoiding [[demyelination]].<ref name="pmid24569125">{{cite journal| author=Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D et al.| title=Clinical practice guideline on diagnosis and treatment of hyponatraemia. | journal=Eur J Endocrinol | year= 2014 | volume= 170 | issue= 3 | pages= G1-47 | pmid=24569125 | doi=10.1530/EJE-13-1020 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24569125 }} </ref> | To prevent central pontine myelinolysis in patients with [[hyponatremia]], the [[hyponatremia]] should be corrected at a rate not exceeding 10 mmol/L/24 h or 0.5 mEq/L/h; or 18 mEq/L/48hrs to minimize the risk of this condition developing from the overly rapid reversal of [[hyponatremia]], thus avoiding [[demyelination]].<ref name="pmid24569125">{{cite journal| author=Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D et al.| title=Clinical practice guideline on diagnosis and treatment of hyponatraemia. | journal=Eur J Endocrinol | year= 2014 | volume= 170 | issue= 3 | pages= G1-47 | pmid=24569125 | doi=10.1530/EJE-13-1020 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24569125 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 18:35, 9 January 2020
|
Central pontine myelinolysis Microchapters |
|
Differentiating Central pontine myelinolysis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Central pontine myelinolysis primary prevention On the Web |
|
American Roentgen Ray Society Images of Central pontine myelinolysis primary prevention |
|
Risk calculators and risk factors for Central pontine myelinolysis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
To prevent central pontine myelinolysis in patients with hyponatremia, the hyponatremia should be corrected at a rate not exceeding 10 mmol/L/24 h or 0.5 mEq/L/h; or 18 mEq/L/48hrs to minimize the risk of this condition developing from the overly rapid reversal of hyponatremia, thus avoiding demyelination.
Primary Prevention
To prevent central pontine myelinolysis in patients with hyponatremia, the hyponatremia should be corrected at a rate not exceeding 10 mmol/L/24 h or 0.5 mEq/L/h; or 18 mEq/L/48hrs to minimize the risk of this condition developing from the overly rapid reversal of hyponatremia, thus avoiding demyelination.[1]
References
- ↑ Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D; et al. (2014). "Clinical practice guideline on diagnosis and treatment of hyponatraemia". Eur J Endocrinol. 170 (3): G1–47. doi:10.1530/EJE-13-1020. PMID 24569125.